Dr Frédéric Caufrier

Helping healthcare companies with medical affairs, medical strategy, and product launches - systemic constellations @3ParallelRivers

[Dr Frédéric Caufrier @Caufrier]

From RSV (respiratory syncytial virus) and PAH (pulmonary arterial hypertension) to the inflammatory bowel disease ulcerative colitis …

The Top 10 Most Anticipated Drug Launches of 2023. https://t.co/U0psrCJjto

[Dr Frédéric Caufrier @Caufrier]

Ten years, five epidemics, one country …

Guinea has suffered outbreaks of Ebola, measles, Lassa Fever and Marburg, as well as COVID-19, over the past decade.

#healthcare https://t.co/2Hy8Qi4dNk

[Dr Frédéric Caufrier @Caufrier]

How to Unlock Creativity

Fascinating Research Alert! 🌟

A study by the University of Arizona reveals that creative individuals effectively utilize idle time to generate groundbreaking ideas. During the COVID-19 pandemic, they remained engaged and les…https://t.co/K9kHATWERc

[Dr Frédéric Caufrier @Caufrier]

Chatbots powered by artificial intelligence used in patient care are regulated as medical devices, but their unreliability precludes approval as such.

📕Link in comment (paywall) https://t.co/4BM48IK0t8

[Dr Frédéric Caufrier @Caufrier]

The Overcommitted Organization

>>> In almost all organisations I worked with, I came across overcommitted teams and overcommitted & strong contributing individuals (who ended up leaving that organisation in most cases).

🔸Burning a candle at both ends h…https://t.co/PGj10Alpfl

[Dr Frédéric Caufrier @Caufrier]

How Generative AI Can Drive Biopharma Strategy

Generative AI holds immense promise for enhancing biopharma strategy, and embracing its transformative potential will be crucial for maintaining a competitive edge. https://t.co/HDzYsIAMMr

[Dr Frédéric Caufrier @Caufrier]

Often overlooked ... but biotech needs labs and thus lab space to make it happen.

It even becomes the limiting factor for growth.

This Reuters article covers the UK situation, but it happens worldwide.

Some innovation clusters try to tackle this issue…https://t.co/xyhJVgO13U

[Dr Frédéric Caufrier @Caufrier]

Revenue model biopharmaceutical companies

The innovative biopharmaceutical companies try to bring small (chemical structured molecules) and/or large molecules (biologics) on the market after an extensive R&D phase, multiple clinical trials (phase 1,2 &…https://t.co/uJYCoMT6Pc

[Dr Frédéric Caufrier @Caufrier]

My grandmother died from TB when she was young and when antibiotics were hardly available.

The situation today is that we have multi-drug resistant TB strains.

As TB is getting more and more a serious health threat, always nice to applaud new approaches…https://t.co/acir0qLndn

[Dr Frédéric Caufrier @Caufrier]

FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

“Roctavian is a one-time gene therapy product administered as a single dose by intravenous infusion. Roctavian consists of a viral vector carrying a gene for clot…https://t.co/m5mogm1tKg https://t.co/ebcBPRH06A

[Dr Frédéric Caufrier @Caufrier]

Imagine ….

Imagine …. the same line of thinking in the pharma industry.

Imagine … the same line of thinking in any industry really. https://t.co/CyYE9p4Yz5

[Dr Frédéric Caufrier @Caufrier]

On foresight and unintended consequences…

“When humanity acquired the ability to imagine the future, it changed the trajectory of our species. But in the age of the Anthropocene, we need to harness this mental skill now more than…https://t.co/4dT8tASw3M https://t.co/tM0m3oouP1

[Dr Frédéric Caufrier @Caufrier]

11 medical device startups to watch, according to investors.

“And while funding levels have dropped in 2023, medical device startups haven’t experienced anything like the dip that sectors like fintech and deeptech have had to grapple with.”

#venturecapi…https://t.co/M7XjRD1Oqv

[Dr Frédéric Caufrier @Caufrier]

Gene editing landscape ✂ https://t.co/rSLd02c1Vm

[Dr Frédéric Caufrier @Caufrier]

“Two new drugs for treating obesity are on course to become available in the next few years — and they offer advantages beyond those of the highly effective blockbuster drugs already on the market.

- The first, called orforglipron, is easier to use and…https://t.co/oqi2KnOz3i

[Dr Frédéric Caufrier @Caufrier]

BelCham is launching of the BelCham Life Sciences Chapter!

"Founded in 1919 by Belgian and American business professionals after the First World War, BelCham has been bridging the gap between two continents for over a century. As the premier partner for…https://t.co/4WlAAZU9vb

[Dr Frédéric Caufrier @Caufrier]

Biotech begins human trials of drug designed by artificial intelligence.

"A biotech company backed by Chinese conglomerate Fosun Group and private equity giant Warburg Pincus has begun one of the first mid-stage human trials of a…https://t.co/9c1ifJEkvp https://t.co/gTyWYzVCec

[Dr Frédéric Caufrier @Caufrier]

Amplifying gene expression with RNA-targeted therapeutics | Nature Reviews Drug Discovery

Recent discoveries of the extensive regulatory networks formed by non-coding RNAs offer alternative targets and strategies to amplify the production of a specific p…https://t.co/J5k5QNYY6j

[Dr Frédéric Caufrier @Caufrier]

🧬On Gene Therapy & Gene Editing:

Two Effective Tools for Addressing Deleterious Genes.

Gene Therapies For Retinal Disorders. https://t.co/QmyMS1x0IS

[Dr Frédéric Caufrier @Caufrier]

Suddenly, It Looks Like We’re in a Golden Age for Medicine.

We may be on the cusp of an era of astonishing innovation — the limits of which aren’t even clear yet. https://t.co/3wcIV8Q2bq